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Cervical cancer is one of the most common cancers in women worldwide, despite 
being identified as one of the most preventable and successfully treatable forms of 
cancers. The majority of deaths could be avoided if women had regular cervical 
screening along with the Human Papillomavirus (HPV) vaccination. Poor education, 
lack of resources, fear and embarrassment, along with cultural traditions, have been 
identified as challenges that prevent women from having the HPV vaccination and 
cervical screening. This report will provide an overview of cervical cancer, whilst 
acknowledging health disparities and the innovations used to tackle these health 
inequalities in the struggle to eradicate cervical cancer. 
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This report will identify the causes of cervical cancer, its signs, symptoms, and the 
current preventative and educational strategies available. The report will analyse 
innovations, and exploring the challenges women face which may inhibit them from 
attending cervical screenings or receiving the Human Papillomavirus (HPV) 
vaccination. The aim is to promote women’s health through contemporary research 
and address these challenges to significantly reduce premature deaths.   
 
Background 
Cervical cancer is identified as a global public health issue with over half a million 
women diagnosed in 2018, with mortality from developing or under developed 
countries accounting for an estimated 85% of deaths, (Small et al., 2017).  Factors 
contributing to the prevalence of cervical cancer have been identified as: failure to 
comply with cervical screening programmes, lack of access, unvaccinated individuals, 
socioeconomic status, healthcare access and cultural beliefs (Hull et al., 2020). The 
World Health Organization (WHO) (2020) acknowledged cervical cancer as the fourth 
most common cancer among women worldwide, despite the effective preventable 
vaccination and cervical screening programme.  
In 2017, there were more than eight new cases of cervical cancer every day in United 
Kingdom (UK), and it is identified as the second most common cancer in women aged 
15-44, (Office for National Statistics [ONS], 2019). The HPV vaccination has been 
highlighted as a primary preventative approach, reducing cervical cancer cases by 
over 70% (PHE, 2019a). In England, the HPV programme has seen a reduction in 
52 
 
HPV types 16 and 18, between the ages of 16-24, from 8.2% in 2010 to 1.6% in 2016 
(Mesher et al., 2018).  
Figures suggest that a health promotion programme including both the HPV 
vaccination and cervical screening can dramatically reduce the prevalence of 
developing cervical cancer and significantly improve life expectancy (Arbyn et al., 
2019). The WHO (2018) estimates that no single intervention strategy such as the 
HPV vaccination can eliminate disease on its own and would only achieve a 0.01% 
reduction in cervical cancer mortality rates by 2030.   
 
Causes of Cervical Cancer 
Over 99% of all cases of cervical cancer are due to infections caused by HPV (Garg 
et al., 2020). HPV is predominantly a result of any skin-to-skin contact of the genital 
area, through vaginal, anal or oral sex, but can be transmitted from an infected person 
via non-sexual means or from mother to child through delivery (Boda et al., 2018, 
Sabeena et al., 2017). There are over 150 types of HPV, of which around 13 can be 
identified as high risk as they are connected to cervical cancer, with HPV 16 and 18 
the leading variants (Lindsay et al., 2020). Over time, HPV can lead to abnormal cells 
in the cervix and when left untreated can develop into cervical cancer, despite 90% of 
cases clearing up independently within two years, without harm (Schiffman et al., 
2016). 
Women who were exposed to diethylstilboestrol (DES) medication before birth are 
also at risk of cervical cancer (National Institutes of Health, 2011). DES was licensed 
to prevent miscarriages over 40 years ago, but was later found to cause a high risk of 
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developing abnormal cells in the cervix in female offspring and annual screenings are 
recommended (Verloop et al., 2010).  
 
Signs and Symptoms 
Symptoms of cervical cancer are vaginal bleeding during or after sex, in between 
periods or after menopause, experiencing pain or discomfort during or after sex, 
vaginal discharge with a strong odour, unexplained weight loss and lower back or 
persistent pelvic pain (Al-Darwish et al., 2014). These symptoms highlight the need to 
attend screening since they are not always present, and it is reported that 49% of UK 
women diagnosed with cervical cancer when screened had previously reported 
symptoms to a health professional, (Aasbo et al., 2019). Consequently, a third of 
women who reported symptoms faced follow-up and treatment delays of around three 
months resulting in poor patient satisfaction (Lim et al., 2014). Experience has 
improved with research, enhancing health professionals’ understanding of the 
symptoms, thereby encouraging them to investigate when previously they may have 
been overlooked (Funston et al., 2018). 
 
Cervical Screening 
Cervical screening first occurred in 1964, with women receiving opportunistic 
screening and those who were found to have cervical cancer received substandard 
follow-ups (Raffle and Muir Gray, 2020). The National Health Service (NHS) produced 
a more effective cervical screening programme in 1988, in order to reduce the rising 
number of cervical cancer diagnoses and mortality rates dropped by approximately 
50% (Albrow et al., 2012).  
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Women aged 20 were invited to attend their first cervical cancer screening and every 
three to five years thereafter until the age of 64, whereby the risk is thought to reduce 
(Albrow et al., 2012,). Castanon et al. (2014) advised screening over 64 is not cost 
effective, believing that only women who have a high risk or show symptoms are 
appropriate candidates for screening. Yost and Hoekstra (2018) however, identified 
that 20% of cervical cancer cases are women over 65, advocating that screening 
should continue and that vaccinating this group would prove cost effective in the long-
term to reduce cases.  
European guidelines for quality assurance (QA) in cervical cancer screening led to a 
more robust UK cervical screening programme in 2004, introducing an organised call 
and recall system for women aged 25-64. Screening was required every three years, 
until the age of 50 where it extended to every five years, until the  programme was 
updated in 2012, inviting women from the age of 24.5 to ensure all women were 
screened by the age of 25 (Chrysostomou et al., 2018, Castanon, Tataru and Sasieni, 
2020). This increase in age caused a public concern, with cervical cancer rates rising 
in women aged 20-24 years,   there were allegations that younger women were 
overlooked, creating inequity in care which went against the ethos of the public health 
strategy for cervical screening (PHE, 2019a, Moscicki et al., 2018). Despite this, the 
policy remains unchanged with studies confirming that screening earlier can cause 







Quality in Screening 
Quality control (QC) and QA are vital in order to instil excellent and reliable standards 
in care, requiring regular monitoring through all the stages of protocols and 
organisations to ensure they are current, safe and effective (Manghani, 2011). All 
steps should be taken in line with trusts’ local policies and procedures whilst adhering 
to national guidelines to eliminate risks and deliver outstanding care (Jhugrsing, 
Dimmock and Mulchandani, 2017). The accuracy of cervical screening is of the utmost 
importance, a liquid based cytology (LBC) test was developed in an improvement to 
the original Papanicolaou (PAP) and now accounts for 90% of the cytology tests taken 
today (Gibb and Martens, 2011).  The LBC was also designed to improve detection of 
cancerous cells, in line with QC, preventing false-negatives in order to initiate 
appropriate treatment and avoid false-positives to avert unnecessary investigations 
(Lim and Woo Yoo, 2019). There is an increased risk of developing cervical cancer 
should a patient receive a false negative. However false positives can also be harmful, 
leading to unnecessary investigations and treatment that not only impact patients’ 
wellbeing but, in some instances, can affect their sexual life and reproductive system 
(Schiffman and Sanjose, 2019).  
Studies have found the quality of the initial PAP test was thwarted by blood, mucus 
and poor cell distribution, leading to errors in detecting and interpreting abnormal cells 
sensitivities (Gibb and Martens, 2011, Jeong et al., 2017). This highlights that women 
must attend screening mid menstrual cycle, to prevent the propensity for false results 
and rescheduling of appointments, (NICE,2020). QA procedures such as staff training, 
evaluation, auditing and reviews of the screening programme can ensure it is safe and 




Barriers to screening 
Barriers that prevent women from attending cervical screening are thought to be 
anticipation of pain or embarrassment, fearing the outcome, accessibility and poor 
patient-nurse relationship (Cooper, 2011).  It is stated the current programme is 
invasive and uncomfortable, resulting in low patient satisfaction and participation 
(Williams et al., 2017). Traditional beliefs, poor understanding, lack of education and 
communication barriers were also identified as challenges to cervical screening 
among Black, Asian and Minority Ethnic (BAME) groups (Ferdous et al., 2018). Certain 
cultures discourage unmarried women from undertaking cervical screening believing 
it will bring dishonour and stigma to the family,  due to HPV’s association with sexually 
transmitted infections (STIs) (Kim, 2014). Some cultural customs forbid women from 
having nurses of the opposite gender attend to them, highlighting the need for cultural 
competence practice (Davies and Thate, 2017). Being aware of cultural customs with 
influenced by religion, older generations or societal beliefs, enables nurses to deliver 
high standards of care to patients and providing women with the appropriate gender 
practitioner to conduct their cervical screening (NHS, 2014).  
A good patient-nurse rapport is also said to encourage women to attend cervical 
screening and avoiding jargon can overcome communication barriers with patients 
(McMunn 2019, Payton, 2018).  
 
Media influence 
Current cervical screening invitations are sent to women with patient information 
leaflets (NICE, 2020). Screening is at a 20-year low, falling below the national target 
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for cervical screening coverage by nearly 10% (NHS Digital, 2020). Therefore, in order 
to promote cervical screening, new innovations are explored with the aim to encourage 
and support more women to take part.  
PHE (2019c) launched a national multimedia campaign called ‘Cervical Screening 
Saves Lives’, in order to promote and encourage more women to attend cervical 
screening by providing information and highlighting the risks of cervical cancer. The 
media has previously had a positive effect and was responsible for a significant 
increase in cervical screening following the publicised story of celebrity Jade Goody, 
who was diagnosed and later died of cervical cancer at the age of 27 in 2008 (Marlow 
et al., 2012). Known as the Jade Goody effect, the following year, attendance in 
England increased to over half a million, but consequently decreased, mirroring the 
pattern of the media coverage (Lancucki et al., 2012). This highlights the success and 
importance of the role the media plays in promoting health and wellbeing, by spreading 
awareness and education (Sharma and Gupta, 2017).  
The ‘Lifesaving Wax campaign’ is partnered with Treatwell (2020), a leading hair and 
beauty company which has targeted over 1.2 million women between the ages of 25-
34 who use salons to maintain pubic hair. It has promoted cervical screening during 
intimate appointments and encouraged women to overcome fear and embarrassment, 
with more than 86,000 more cervical screenings recorded since the campaign started, 






Innovations in Cervical Screening  
NHS England (2021) is trialling YouScreen, a HPV home testing self-sampling kit that 
will be available to over 31,000 women in England, aged between 25-64. YouScreen 
will be offered to women whose screening is overdue by 6-15 months often as a 
consequence of COVID, to improve uptake as part of a study in North Central and 
North East London, (NHS England, 2021). Castanon et al (2020) acknowledged 
COVID-19 delays and emphasised that there must be equity in care for those affected 
by screening delays in addition to extra screening capacity. Youscreen may be an 
innovation to help address this imbalance by increasing uptake. However, Wong et 
al., (2018) suggests home tests could be financially ineffective and unsafe, leading to 
inaccurate results or unnecessary investigations. The effectiveness of YouScreen is 
unclear, although a developing evidence base from predominantly high-income 
countries suggests self-sampling can increase screening uptake compared with 
standard care, yet more evidence is needed to establish accuracy and reliability of 
results (Yeh et al 2019, Chao and MCcormack, 2019). 
 Another innovation is ZedScan, a new diagnostic tool designed to be less-invasive 
during colposcopy (Peron et al., 2018). Its probe is used to capture images of the 
cervix in real time, allowing healthcare professionals to make a real time accurate and 
informed decision by identifying any precancerous cells (NICE, 2018). ZedScan has 
been seen to reduce unnecessary biopsies and improve patient satisfaction. The early 
detection can support positive patient outcomes although there is a high risk of 








HPV is responsible for nearly all cases of cervical cancer and the prophylactic 
vaccination protects against the main strains of HPV 16 and 18, plus HPV 6 and 11, 
which are responsible for 90% of anal, genital, head and neck cancers (Cubie, 2013). 
The HPV vaccination programme was introduced in 2008, targeting girls in England 
aged 12-13 years, therefore the full impact of the vaccine and its effects on cancer 
survival rates may not be realised for years to come, (Cervantes and Doan, 2018) . 
Since its introduction cervical cancer cases have fallen but not all strains of HPV are 
covered and it is important women still attend cervical screenings (Henderson et al., 
2011).   
The rate of girls having the HPV vaccination fell in 2017-2018 to 86.9%, compared to 
89.4% in 2014-2015 (PHE, 2018b).  The vaccination may have triggered ethical 
dilemmas for parents because of the age it is administered to children. Some parents 
believe that by promoting the HPV vaccination, they are encouraging sexual 
relationships and risky behaviour at an inappropriate age, but studies dispute this 
(Donken et al., 2018).  Cross sectional and longitudinal surveys in England highlighted 
that neither receiving the vaccine nor being offered it affected a girl’s sexual behaviour 
(Forster et al, 2012). In England, the programme is rolled out in schools with a health 
education and promotion focus, which may account for a significantly higher uptake 
then alternative non-school-based schemes (Hopkins and Wood, 2013). Promoting 
awareness to parents about HPV and its link to different cancers and genital warts 
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enables parents to make an informed decision regarding the vaccination (Ganczak, 
Owsianka and Korzeń, 2018). Furthermore, poor education in parents appeared to be 
a common factor, as to why parents did not allow their children to have the HPV 
vaccination (Griffioen et al., 2012). It had been suggested that BAME communities 
have a lower vaccine uptake, with parents not agreeable to the HPV vaccination due 
to strong religious beliefs about sex outside of marriage (Forster et al., 2017). 
Research demonstrates these communities would benefit from tailored education to 
promote vaccination (Netfa et al., 2020).  
The vaccination engages more people when dual prevention of both HPV and cervical 
cancer is promoted and it was announced that the HPV vaccination would be available 
to boys from the age of 12-13 years, in England, from 2019 (Merriel et al., 2018), 
Cartmell et al., 2018). The strategy of extending the HPV vaccination programme to 
boys acknowledges the value of prevention and early intervention, yet the results of 
this development will not be determined for some time, (Every Child Matters, 2003, 




The HPV vaccination has been acknowledged as a primary preventative innovation 
in reducing the risk of cervical cancer. Cervical screening is a proven invaluable tool 
in preventing cervical cancer in women, with both the NHS and WHO having 
identified the programme as a primary strategy to eradicate cervical cancer. 
Challenges to the success of both cervical screening and HPV vaccination uptake 
have been highlighted as a lack of education in some communities. Healthcare 
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professionals require cultural competence in order to effectively address parental 
concerns and encourage uptake of cervical screening and HPV vaccination. Moving 
forward it is clear that many barriers to cervical screening need to be overcome.  
Patient focused strategies are key, such as ensuring privacy and dignity, offering a 
chaperone to all women as standard practice, demonstrating responsiveness within 
the assessment process to reassure and actively address patient concerns. Further 
encouragement to engage and overcome practical challenges such as the 
introduction of self-testing home kits show potential for increasing screening 
participation, as do the introduction of vaccinations to boys. These will inevitably 
require research to establish its impact on cervical and associated cancer rates 






Aasbo, G., Solbrække, K.N., Waller, J., Trope, A., Nygard M. and Hansen, B.T. (2019) 
Perspectives of non-attenders for cervical cancer screening in Norway: a qualitative 
focus group study. BMJ Open, 9(8), pp1-8.  
 
Albrow, R., Kitchener, H., Gupta, N. and Desai, M. (2012) Cervical screening in 
England: The past, the present and future. Cancer Cytopathology, 120(2), pp.87-96.  
 
Al-Darwish, A.A., Al-Naim, A.F., Al-Mulhim, K.S., Al-Otaibi, N.K., Morsi, M.S. and 
Aleem, A.M. (2014) Knowledge about Cervical Cancer Early Warning Signs and 
52 
 
Symptoms, Risk Factors and Vaccination among Students at a Medical School in Al-
Ahsa, Kingdom of Saudi Arabia. Asian Pacific Journal of Cancer Prevention, 15(6), 
pp.2529–2532.  
 
Arbyn, M., Anttila, A., Jordan, J., Ronco, G., Schenck, U., Segnan, N., Wiener, H., 
Herbert, A. and Von Karsa, L. (2010) European Guidelines for Quality Assurance in 
Cervical Cancer Screening. Second Edition— Summary Document. Annals of 
Oncology, 21(3), pp.448-458. 
 
Arbyn, M., Weiderpass, E., Bruni, L., Sanjosé, S., Saraiya, M., Ir, J.F. and Bray, F. 
(2019) Estimates of incidence and mortality of cervical cancer in 2018: a worldwide 
analysis. Lancet Global Health, 8(2), pp.E191-E203.  
 
Boda, D., Docea, A.O., Calina, D., Ilie, M.A., Caruntu, C., Zurac, S., Neagu, M., 
Constantin, C., Branisteanu, D.E., Voiculescu, V., Mamoulakis, C., Tzanakakis, G., 
Spandidos, D.A., Drakoulis, N. and Tsatsakis, A.M. (2018) Human papilloma virus: 
Apprehending the link with carcinogenesis and unveiling new research avenues 
(Review). International Journal of Oncology, 52(3), pp.637–655.  
 
Byrom, J., Dunn, P., Ferguson, G., Leeson, S., Redman, C., Smith, J. and Tidy, J. 
(2020) Using technology to harmonise treatment approaches in colposcopy in the face 
of a changing environment. European Journal of Obstetrics and Gynaecology and 




Cartmell, K.B., Young-Pierce, J., McGue, S., Alberg, A.J., Luque, J.S., Zubizarreta, M. 
and Brandt, H.M. (2018) Barriers, facilitators, and potential strategies for increasing 
HPV vaccination: A state-wide assessment to inform action. Papillomavirus Research, 
5, pp.21–31.  
 
Castanon, A., Landy, R., Cuzick, J. And Sasieni, P. (2014) Cervical Screening at Age 
50–64 Years and the Risk of Cervical Cancer at Age 65 Years and Older: Population-
Based Case Control Study. Public Library of Science Medicine, 11(1), pp.1-13.  
 
Castanon, A. and Sasieni, P. (2018) Is the recent increase in cervical cancer in women 
aged 20-24years in England a cause for concern? Preventive Medicine, 107, pp.21–
28.  
 
Castanon, A., Tataru, D. and Sasieni, P. (2020) Survival from Cervical Cancer 
Diagnosed Aged 20–29 Years by Age at First Invitation to Screening in England: 
Population-Based Study. Cancers, 12(8), p.2079.  
 
Castanon, A., Matejka,R., Pesola, F and Sasieni, P (2020) The impact of COVID-19 
disruption to cervical cancer screening in England on excess diagnoses 
medRxiv 2020.11.30.20240754;  
 
Cervantes, J.L. and Doan, A.H. (2018) Discrepancies in the evaluation of the safety of 





Chao, Y.S. and McCormack, S. (2019) HPV Self-Sampling for Primary Cervical 
Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An 
Update. [online] Available at: https://www.ncbi.nlm.nih.gov/books/NBK545378/ 
[Accessed 23rd March 2021] 
 
Chrysostomou, K., Stylianou, D.C., Constantinidou, A. and Kostrikis, L.G. (2018) 
Cervical Cancer Screening Programs in Europe: The Transition Towards HPV 
Vaccination and Population-Based HPV Testing. Viruses, 10(12), p.729.  
 
Cooper, M. (2011) Reasons for non-attendance at cervical screening. Nursing 
Standard, 25(26), pp.41-46. 
 
Cubie, H.A. (2013) Diseases associated with human papillomavirus infection. 
Virology, 445(1-2), pp.21-34.  
 
Davies, D.J. and Thate, M.J. (2017) Religion and the Individual: belief, practice, and 
Identity. MDPI AG: Basel, Switzerland. 
 
Department of Health and Social Care (2018) Prevention is better than cure: Our 
vision to help you live well for longer.  
 




Donker, R., Ogilvie, G.S., Bettinger, J.A., Sadarangani, M. and Goldman, R.D. (2018) 
Effect of human papillomavirus vaccination on sexual behaviour among young 
females. Canadian Family Physician, 64(7), pp.501-513. 
 
El-Zein, M., Bouten, S., Louvanto, K., Gilbert, L., Gotlieb, W., Hemmings, R., Behr, 
M.A., Franco, E., CASSIS Study Group. (2018) Validation of a new HPV self-sampling 
device for cervical cancer screening: The Cervical and Self-Sample in Screening 
(CASSIS) study. Gynaecologic Oncology, 149(3), pp.491-497  
 
Ferdous, M., Lee, S., Goopy, S., Yang, H., Rumana, N., Abedin, T. and Turin, T.C. 
(2018) Barriers to cervical cancer screening faced by immigrant women in Canada: a 
systematic scoping review. BMC Women's Health, 18(165), pp.1-13.  
 
Forster, A. S, Marlow, L. A.V, Stephenson, J., Wardle, J, and Waller, J. (2012) "Human 
Papillomavirus Vaccination and Sexual Behaviour: Cross-sectional and Longitudinal 
Surveys Conducted in England." Vaccine 30.33: 4939-944.  
 
Forster, A. S., Rockliffe, L., Marlow, L., Bedford, H., McBride, E. and Waller, J. (2017) 
Exploring human papillomavirus vaccination refusal among ethnic minorities in 
England: A comparative qualitative study. Psycho-oncology, 26(9), pp.1278–1284.  
 
Funston, G., O’Flynn, H., Ryan, N.A.J., Hamilton, W. and Crosbie, E.J. (2018) 
Recognizing gynecological cancer in primary care: risk factors, red flags, and referrals. 




Ganczak, M., Owsianka, B. and Korzeń, M. (2018) Factors that Predict Parental 
Willingness to Have Their Children Vaccinated against HPV in a Country with Low 
HPV Vaccination Coverage. International journal of environmental research and public 
health, 15(4), 645.  
 
Garg, A., Galvin, A.M., Matthes, S. and Thompson, E.L. (2020) The connection 
between social determinants of health and Human Papillomavirus testing knowledge 
among women in the USA. Journal of Cancer Education.  
 
Gibb, R. and Martens, M. (2011) The impact of liquid-based cytology in decreasing the 
incidence of cervical cancer. Reviews in Obstetrics & Gynecology, 4(1), pp.2-11. 
 
Griffioen, A.M., Glynn, S., Mullins, T.K., Zimet, G.D., Rosenthal, S.L., Fortenberry, J.D. 
and Khan, J.A. (2012) Perspectives on Decision Making About Human Papillomavirus 
Vaccination Among 11- to 12-Year-Old Girls and Their Mothers. Clinical Paediatrics, 
51(6), pp.560-568.  
 
Gwynn, S. (2019) Public Health England partners Treatwell for 'Life saving wax' 
initiative. [online] Available at: https://www.campaignlive.co.uk/article/public-health-
england-partners-treatwell-life-saving-wax-initiative/1582926 [Accessed 30th October 
2020] 
 
Henderson, L., Clements, A., Damery, S., Wilkinson, C., Austoker, J. and Group, S.W. 
(2011) A False Sense of Security? Understanding the role of the HPV vaccine on 
52 
 
future cervical screening behaviour: A qualitative study of UK parents and girls of 
vaccination age. Journal of Medical Screening, 18(1), pp.41-45.  
 
Hopkins, T.G. and Wood, N. (2013) Female human papillomavirus (HPV) vaccination: 
global uptake and the impact of attitudes. Vaccine, 31(13), pp.1673–1679. 
 
HM Treasury (2003) Every Child Matters. [online] Available 
at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/atta
chment_data/file/272064/5860.pdf [Accessed 8th December 2020] 
 
Hull, R., Mbele, M., Makhafola, T., Hicks, C., Wang, S.M., Reis, R.M., Mehrotra, R., 
Mkhize-Kwitshana, Z., Kibiki, G., Bates, D.O. and Dlamini, Z. (2020) Cervical cancer 
in low and middle-income countries. Oncology Letters, 20(3), pp.2058–2074.  
 
Jeong, H., Hong, S.R., Chae, S. W., Jin, S.Y., Yoon, H.K., Lee, J., Kim, E.K., Ha, S.T., 
Kim, S.N., Park, E.J., Jung, J.J., Sung, S.H. and Lim, S.C. (2017) Comparison of 
Unsatisfactory Samples from Conventional Smear versus Liquid-Based Cytology in 
Uterine Cervical Cancer Screening Test. Journal of Pathology and Translational 
Medicine, 51(3), pp.314–319.  
 
Jhugursing, M., Dimmock, V. And Mulchandani, H. (2017) Error and root cause 




Kim, H.W. (2014) Awareness of Pap testing and factors associated with intent to 
undergo Pap testing by level of sexual experience in unmarried university students in 
Korea: results from an online survey. BMC Women’s Health, 14(100), pp.1-13. 
 
Lancucki, L., Sasieni, P., Patnick, J., Day, T.J. and Vessey, M.P. (2012) The impact 
of Jade Goody's diagnosis and death on the NHS Cervical Screening Programme. 
Journal of Medical Screening, 19(2), pp.89–93.  
 
Lim, A.W., Ramirez, A.J., Hamilton, W., Sasieni, P., Patnick, J. and Forbes, L.J. (2014) 
Delays in diagnosis of young females with symptomatic cervical cancer in England: an 
interview-based study. The British Journal of General Practice: the journal of the Royal 
College of General Practitioners, 64(627), pp. e602–e610.  
 
Lim, S. and Woo Yoo, C. (2019) Current Status of and Perspectives on Cervical 
Cancer Screening in Korea. Journal of Pathology and Translational Medicine, 53(4), 
pp.210–216.   
 
Lindsay, A.C., Delgado, D., Valdez, M.J. Restrepo, E. and Guzzman, Y.M. (2020) I 
don’t Think He Needs the HPV Vaccine because Boys Can’t Have Cervical Cancer: A 
Qualitative Study of Latina Mothers’ (Mis) Understandings About Human 
Papillomavirus Transmission, Associated Cancers, and the Vaccine. Journal of 





Manghani, K. (2011) Quality assurance: Importance of systems and standard 
operating procedures. Perspectives in Clinical Research, 2(1), pp.34-37.  
 
Marlow, L.A.V., Sangha, A., Patnick, J. and Waller, J. (2012) The Jade Goody Effect: 
Whose Cervical Screening Decisions Were Influenced by Her Story? Journal of 
Medical Screening, 19(4), pp.184-188.  
 
 
McMunn, V. (2019) Improving women’s uptake of cervical screening in primary care. 
Primary Health Care. Nursing Standard, 30(5), pp.1-7.  
 
Merriel, S.W., Nadarzynski, T., Kesten, J.M., Flannagan, C. and Prue, G. (2018). Jabs 
for the boys: time to deliver on HPV vaccination recommendations. The British Journal 
of General Practice, 68(674), pp.406–407.  
 
Mesher, D., Panwar, K., Thomas, S., Edmundson, C., Choi, Y.H., Beddows, S. and 
Soldan, K. (2018) The Impact of the National HPV Vaccination Program in England 
Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young 
Females, 2010–2016, The Journal of Infectious Diseases, 218(6), pp.911–921. 
 
Moscicki, A. B., Perkins, R. B., Saville, M. and Brotherton, J. (2018) Should Cervical 
Cancer Screening be Performed Before the Age of 25 Years? Journal of lower genital 




National Health Service Digital (2020) Cervical Screening Programme - Coverage 
Statistics [Management Information].  
 
National Health Service England (2021) NHS gives women Human Papillomavirus 
Virus (HPV) home testing kits to cut cancer deaths [online] Available at: 
https://www.england.nhs.uk/2021/02/nhs-gives-women-hpv-home-testing-kits-to-cut-
cancer-deaths/ [Accessed 23rd March 2021] 
 
National Institutes of Health (2011) Women exposed to DES in the womb face 
increased cancer risk. 
 
National Institute for Health and Care Excellence (2018) Adjunctive colposcopy 
technologies for assessing suspected cervical abnormalities: the DYSIS colposcope 
with DYSIS map and the ZedScan.  
 
National Institute for Health and Care Excellence (2020) Cervical Screening.  
 
National Institute for Health and Care Excellence (2020b) Human Papillomavirus 
Vaccines.  
 
Netfa, F., Tashani, M., Booy, R., King, C., Rashid, H. and Skinner, S. R. (2020) 
Knowledge, Attitudes and Perceptions of Immigrant Parents Towards Human 
Papillomavirus (HPV) Vaccination: A Systematic Review. Tropical Medicine and 




Office for National Statistics (2019) Cancer registration statistics, England: 2017.  
 
Payton, J. (2018) Improving Communication Skills within the Nephrology Unit. 
Nephrology Nursing Journal, 45(3), pp.269-272. 
 
Peron, M., Llewellyn, A., Moe-Byrne, T., Walker, S., Walton, M. Harden, M., Palmer, 
S. and Simmonds, M. (2018) Adjunctive colposcopy technologies for assessing 
suspected cervical abnormalities: systematic reviews and economic evaluation. 
National Institute for Health Research, 22(54), pp.6-31. 
 
Public Health England (2018b) Human papillomavirus (HPV) vaccination coverage in 
adolescent females in England: 2017/18 Report for England.  
 
Public Health England (2019b) Cervical screening: programme overview.  
 




Raffle, A.E. and Muir Gray, J.A. (2020) The 1960s cervical screening incident at 
National Women’s Hospital, Auckland, New Zealand: insights for screening research, 





Schiffman, M. and Sanjose, S. (2019) False positive cervical HPV screening test 
results. Papillomavirus Research, 7, pp.184-187. 
 
Sharma, S.K. and Gupta, Y.K. (2017) Mass Media for Health Education (A Study in 
the State of Rajasthan). Multidisciplinary International Journal, 1(1), pp.26-39. 
 
Small, W., Jr, Bacon, M.A., Bajaj, A., Chuang, L.T., Fisher, B.J., Harkenrider, M.M., 
Jhingran, A., Kitchener, H.C., Mileshkin, L.R., Viswanathan, A.N. and Gaffney, D.K. 
(2017) Cervical cancer: A global health crisis. Cancer, 123, pp.2404-2412.  
 
Stubbs, R. and Pearmain, P. (2019) Cervical screening saves lives – highlights from 
the nation campaign. PHE Screening [blog], 13th September 2019.  
 
Treatwell (2020) Lifesaving wax. [online] Available at: 
https://www.treatwell.co.uk/inspiration/lifesavingwax/faqs/ [Accessed 30th October 
2020] 
 
Verloop, J., van Leeuwen, F.E., Helmerhorst, T.J., van Boven, H.H. and Rookus, M.A. 
(2010) Cancer risk in DES daughters. Cancer causes and control, 21(7), pp.999–1007.  
 
 
Williams, D., Davies, M., Fiander, A., Farewell, D., Hillier, S. and Brain, K. (2017) 
Women's perspectives on human papillomavirus self-sampling in the context of the 
UK cervical screening programme. Health expectations: an international journal of 




Wong, E.L.Y. Cheung, A.W.L., Huang, F. and Chor, J. (2018) Can Human 
Papillomavirus DNA Self-sampling be an Acceptable and Reliable Option for Cervical 
Cancer Screening in Female Sex Workers? Cancer Nursing: 41(1), pp.45-52.  
Yeh, P.T, Kennedy, C.E, De Vuyst, H and Narasimhan, M (2019) Self-sampling for 
human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ 
Global Health 2019;4:e001351.  
 
World Health Organization (2018) To eliminate cervical cancer in the next 100 years, 
implementing an effective strategy is critical.  
 
World Health Organization (2020) Cervical Cancer. [online] Available at: 
https://www.who.int/health-topics/cervical-cancer#tab=tab_1 [Accessed 11th October 
2020] 
 
Yost, S. and Hoekstra, A. (2018) Cervical cancer in women over 65: An analysis of 
screening. Gynaecologic Oncology Reports, 25, pp.48-51. DOI: 
10.1016/j.gore.2018.05.010 
 
 
 
 
 
 
 
52 
 
 
 
